Hypoxia-Selective Antitumor Agents. 14. Synthesis and Hypoxic Cell Cytotoxicity of Regioisomers of the Hypoxia-Selective Cytotoxin 5-[N,N-Bis(2-chloroethyl)amino]-2,4-dinitrobenzamide-Reference-Cited by-同舟云学术

Hypoxia-Selective Antitumor Agents. 14. Synthesis and Hypoxic Cell Cytotoxicity of Regioisomers of the Hypoxia-Selective Cytotoxin 5-[N,N-Bis(2-chloroethyl)amino]-2,4-dinitrobenzamide

Published:1996-01-01 Issue:13 Volume:39 Page:2518-2528
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Palmer Brian D.¹,Wilson William R.¹,Anderson Robert F.¹,Boyd Maruta¹,Denny William A.¹

Affiliation:

1. Cancer Research Laboratory, Department of Pathology, and Department of Chemistry, The University of Auckland School of Medicine, Private Bag 92019, Auckland, New Zealand

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm960057p

Reference27 articles.

1. Vol 3;Wilson W. R.,1992

2. Bioreductive drugs for cancer therapy: The search for tumor specificity

3. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs)

4. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy;Pharmaceuticals;2022-02-02

2. Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3;Pharmaceuticals;2021-11-26

3. Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit;Cancer Gene Therapy;2021-11-26

4. Synthesis and evaluation of new dinitrobenzamide mustards in human prostate cancer;Bioorganic & Medicinal Chemistry Letters;2021-01

5. Overcoming Radioresistance: Small Molecule Radiosensitisers and Hypoxia-activated Prodrugs;Clinical Oncology;2019-05